Tectonic Therapeutic, Inc. (TECX): Shareholders' Equity
$251.33M
As of 2025-12-31
$223.85M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $251.33M | +78.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $140.78M | n/m | 2026-02-26, Balance as of period end |
| 2023-12-31 | -$84.64M | n/c | 2025-03-20, Balance as of period end |
| 2022-12-31 | $75.37M | -55.5% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $169.48M | -33.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $254.34M | +36.7% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $186.01M | +52.2% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $122.18M | n/m | 2020-03-16, Balance as of period end |
| 2017-12-31 | -$23.14M | n/a | 2019-03-25, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $251.33M | +78.5% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $61.01M | n/m |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $246.67M | +111.1% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $196.08M | -34.6% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $241.54M | +257.6% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $11.85M | -70.0% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$5.79M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $186.29M | +741.1% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $168.77M | +516.2% |
Compare TECX, CHRS, LXEO, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗